Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Placebo-controlled, Double-blind, Dose-escalation/Dose-optimization Trial to Evaluate Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-associated Virus (AAV) Capsid

NCT00888446 is registered in ClinicalTrials.gov with International AIDS Vaccine Initiative as lead sponsor.

NCT NCT00888446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00888446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Placebo-controlled, Double-blind, Dose-escalation/Dose-optimization Trial to Evaluate Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-associated Virus (AAV) Capsid
Lead sponsor
International AIDS Vaccine Initiative
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
December 31, 2007
Enrollment
91 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, human immunodeficiency virus infections